What this pack is
CALAN / verapamil immediate-release is the brand name in this record; verapamil hydrochloride immediate-release tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
CALAN / verapamil immediate-releaseGeneric nameverapamil hydrochloride immediate-release tablets
How this medicine works
The label classifies verapamil as a calcium-ion influx inhibitor/slow-channel blocker. It can affect arterial smooth muscle, myocardial contraction and conduction cells. This helps explain why blood pressure, slower heart rate, conduction block and heart-failure risk must be reviewed together, but it cannot predict an individual's response or generate a dose.
Read source: United States ↗Current regulatory record · reviewed 2026-09-02More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- CALAN / verapamil immediate-release
- Source-scoped market brand names
- CALAN · United StatesHistorical regulator record ↗Historical originator/RLD under NDA 018817. The 40, 80, 120 and 160 mg immediate-release tablets are listed as DISCN and marked as not withdrawn for safety or effectiveness. This page does not display a historical original-brand pack.
- verapamil hydrochloride tablets · United StatesCurrent regulator record ↗Current Chartwell RX generic label under ANDA 071881: one 90-tablet bottle each for 40, 80 and 120 mg. A regulatory label is not live stock.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- verapamil hydrochloride immediate-release tablets
- Dosage-form class
- Verapamil hydrochloride immediate-release oral tablets. CALAN SR, VERELAN, VERELAN PM, COVERA-HS, ISOPTIN SR, other extended-release or chronotherapeutic products and injections are separate exact products. A shared generic name or milligram figure does not establish conversion, frequency, splitting, combination or substitution.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed generic label (page updated 10 Dec 2025; text revised Aug 2023)
40 mg verapamil hydrochloride per tablet; 90-tablet bottle
- Product code
- NDC 62135-743-90
- Form and route
- verapamil hydrochloride immediate-release film-coated oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- verapamil hydrochloride
- 40 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting instruction or conversion to CALAN SR, VERELAN, VERELAN PM, another extended-release product or an injection
- Package
- 90 tablets per bottle
- Labelled appearance
- white · round immediate-release film-coated tablet · imprint HP59Unscored; no permission to split it yourself is established
United States label · Current U.S. DailyMed generic label (page updated 10 Dec 2025; text revised Aug 2023)
80 mg verapamil hydrochloride per tablet; 90-tablet bottle
- Product code
- NDC 62135-744-90
- Form and route
- verapamil hydrochloride immediate-release film-coated oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- verapamil hydrochloride
- 80 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting instruction or conversion to CALAN SR, VERELAN, VERELAN PM, another extended-release product or an injection
- Package
- 90 tablets per bottle
- Labelled appearance
- white · round immediate-release film-coated tablet · imprint HP;26Scored appearance clue; not permission to split it yourself
United States label · Current U.S. DailyMed generic label (page updated 10 Dec 2025; text revised Aug 2023)
120 mg verapamil hydrochloride per tablet; 90-tablet bottle
- Product code
- NDC 62135-745-90
- Form and route
- verapamil hydrochloride immediate-release film-coated oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- verapamil hydrochloride
- 120 mglabelled amount per tablet; not an individual's tablet count, frequency, splitting instruction or conversion to CALAN SR, VERELAN, VERELAN PM, another extended-release product or an injection
- Package
- 90 tablets per bottle
- Labelled appearance
- white · round immediate-release film-coated tablet · imprint HP;27Scored appearance clue; not permission to split it yourself
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
Verapamil enlarged label: per-tablet mg, bottle count, heart rate/conduction, constipation and medicine-list review
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 40, 80 and 120 mg figures are amounts per tablet; 90 Tablets is the bottle count. The current 40 mg generic tablet is unscored and the 80/120 mg tablets are scored, but a score is an exact-product appearance and label clue, not automatic permission to self-split. Historical CALAN 80 mg score labelling cannot be extended to another manufacturer, strength or extended-release product.
- Hypotension, dizziness, syncope, bradycardia or atrioventricular block can increase fall and acute risk. Older adults, people using several medicines or those with heart-rate/conduction problems should have pulse, symptoms, every pack and the prescription reviewed together. Severe fainting, chest pain, breathing difficulty or altered awareness needs local emergency care.
- The label warns about heart failure and impaired cardiac contractility. If a beta blocker, digoxin, clonidine, amiodarone or another heart-rate/conduction/blood-pressure medicine is also present, do not self-space, add, reduce, alternate or choose one to stop first.
- Constipation is common, and the label also records rare non-obstructive paralytic ileus. Persistent distension, severe abdominal pain, vomiting or inability to pass gas or stool needs timely medical assessment, not only a web search for a laxative plan.
- The label lists interaction cues with simvastatin, lovastatin and other CYP3A4 substrates/inhibitors, digoxin, lithium and grapefruit juice. The site does not decide co-use, dose reduction or timing from two medicine or food names.
- Immediate-release tablets and products such as CALAN SR, VERELAN, VERELAN PM and COVERA-HS differ in release and labelling. Do not treat a shared generic name, similar milligrams or wording such as once daily as a conversion table.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. generic label for verapamil hydrochloride immediate-release 40/80/120 mg tablets, three 90-tablet bottle NDCs and three exact package panels (ANDA 071881; updated Dec 2025) ↗Current regulatory record · reviewed 2026-09-02
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-09-02FDA: historical CALAN (verapamil hydrochloride) immediate-release oral-tablet label under NDA 018817 (2009 version) ↗reviewed 2026-09-02
- FDA · United States · Regulatory product record or label archive · 2026-09-02FDA Orange Book 46th Edition (2026): CALAN immediate-release oral tablets under NDA 018817 at 40/80/120/160 mg listed in the Discontinued Drug Product List ↗Current regulatory record · reviewed 2026-09-02
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about CALAN / verapamil immediate-release (verapamil hydrochloride immediate-release tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
CALAN / verapamil immediate-release is the brand in this record and verapamil hydrochloride immediate-release tablets is the active-ingredient name. Check both with the dosage form (Verapamil hydrochloride immediate-release oral tablets. CALAN SR, VERELAN, VERELAN PM, COVERA-HS, ISOPTIN SR, other extended-release or chronotherapeutic products and injections are separate exact products. A shared generic name or milligram figure does not establish conversion, frequency, splitting, combination or substitution.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. generic label for verapamil hydrochloride immediate-release 40/80/120 mg tablets, three 90-tablet bottle NDCs and three exact package panels (ANDA 071881; updated Dec 2025) ↗Current regulatory record · reviewed 2026-09-02
- FDA: historical CALAN (verapamil hydrochloride) immediate-release oral-tablet label under NDA 018817 (2009 version) ↗reviewed 2026-09-02
- FDA Orange Book 46th Edition (2026): CALAN immediate-release oral tablets under NDA 018817 at 40/80/120/160 mg listed in the Discontinued Drug Product List ↗Current regulatory record · reviewed 2026-09-02
HOW IT WORKS · NOT A TREATMENT PLAN
How verapamil works: slow calcium-channel blockade affects vessels, myocardium and cardiac conduction
- Sharing the nondihydropyridine calcium-channel-blocker class with diltiazem does not permit milligram conversion, same-day alternation or combination. They remain different ingredients, products, labels and prescriptions.
- A shared effect on heart rate or pressure does not permit self-combining verapamil with a beta blocker, digoxin, clonidine or amiodarone. Heart rate, ECG conduction, cardiac function, pressure, liver function and the complete medicine list need joint review.
- Mechanism cannot decide who is suited to verapamil or use one blood-pressure or pulse reading to decide an increase, decrease or stop. The site only helps identify the exact product, source and label boundary.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. generic label for verapamil hydrochloride immediate-release 40/80/120 mg tablets, three 90-tablet bottle NDCs and three exact package panels (ANDA 071881; updated Dec 2025) ↗Current regulatory record · reviewed 2026-09-02
- FDA: historical CALAN (verapamil hydrochloride) immediate-release oral-tablet label under NDA 018817 (2009 version) ↗reviewed 2026-09-02
- FDA: CALAN NDA 018817/S-035 supplemental approval letter (2021; 80 mg score functionality and labelling update) ↗reviewed 2026-09-02
- FDA Orange Book 46th Edition (2026): CALAN immediate-release oral tablets under NDA 018817 at 40/80/120/160 mg listed in the Discontinued Drug Product List ↗Current regulatory record · reviewed 2026-09-02
SOURCE-TRACEABLE ARCHIVE
CALAN / verapamil immediate-releaseverapamil hydrochloride immediate-release tablets
This page includes an exact current U.S. public-label package panel for CALAN / verapamil immediate-release, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
U.S. approval of CALAN 80/120 mg immediate-release tablets
The FDA Orange Book records approval of NDA 018817 80 mg and 120 mg tablets in 1984.
FDA Orange Book 46th Edition (2026): CALAN immediate-release oral tablets under NDA 018817 at 40/80/120/160 mg listed in the Discontinued Drug Product List ↗Approval of CALAN 40/160 mg immediate-release tablets
The FDA Orange Book records approval of NDA 018817 40 mg and 160 mg tablets in 1988.
FDA Orange Book 46th Edition (2026): CALAN immediate-release oral tablets under NDA 018817 at 40/80/120/160 mg listed in the Discontinued Drug Product List ↗FDA approved the 80 mg score-function labelling update
The supplement letter supports the exact CALAN 80 mg product's labelling history and does not create general splitting permission for other verapamil tablets.
FDA: CALAN NDA 018817/S-035 supplemental approval letter (2021; 80 mg score functionality and labelling update) ↗Current Chartwell RX generic page updated
The current ANDA 071881 page lists three 90-tablet bottles for 40, 80 and 120 mg with exact package panels.
DailyMed (NLM): current U.S. generic label for verapamil hydrochloride immediate-release 40/80/120 mg tablets, three 90-tablet bottle NDCs and three exact package panels (ANDA 071881; updated Dec 2025) ↗
MARKET SCOPE
Market-record boundary
United States — CALAN immediate-release tablets
Historical originator/RLD; discontinuedNDA 018817; 40, 80, 120 and 160 mg are listed as DISCN and footnoted as not withdrawn for safety or effectiveness.
United States — current generic
Current public generic labelANDA 071881; one 90-tablet bottle each for 40, 80 and 120 mg.
Extended-release, chronotherapeutic and injectable products
Separate exact productsCALAN SR, VERELAN, VERELAN PM, COVERA-HS, ISOPTIN SR and injections are not merged into this immediate-release dossier and no conversion is established.
Markets outside the United States
Local brand, strength, pack and supply are not establishedLocal names such as Isoptin must be checked item by item against the local regulator, current label and pack in hand.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Is the pictured bottle the original CALAN product?
No. The image is a current Chartwell RX generic package panel under ANDA 071881. CALAN is shown only as the historical originator/RLD identity.
Does 90 Tablets mean taking 90 tablets at once?
No. 90 Tablets is the bottle count; 40/80/120 mg is the labelled amount per tablet. The site does not turn bottle count or milligrams into an individual's tablet count or frequency.
Does a score always mean the tablet can be split?
No. A score is exact-product appearance and label information. Splitting, storage after splitting and prescription fit require the exact manufacturer's current label, prescription and pharmacist review. An immediate-release score must never be extended to an extended-release product.
Can verapamil and diltiazem be alternated?
The site cannot create alternation or conversion from a shared class. They are different ingredients and prescriptions, and both can affect heart rate, conduction, pressure and interactions; the complete medicine list and clinical context require joint review.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.